18 annual accounts with figures on one time axis, 25 filings since 2000
peak of €145,935 in 2024
€145,935▲ 11×
lowest -€14,893 in 2008
€99,140▲ €100,256
peak of €199,242 in 2024
€199,242▲ 99.0%
€94,394▲ 14.5%
peak of 0.2 FTE in 2007
-not published
Board2 names since 2023
1 directorName after signing inVisible after signing in
Owners
100%Hidden nameVisible after signing in
Documentsfilings and deeds
23-06-202538 days before the deadline
2024financial year
Gross margin from €13,054 to €145,935Profit of €99,140, after a lossRegistered-office move22-04Name hiddenVisible after signing in changes role from manager to director29-021 director appointed, 1 statutory auditor appointed, 1 resign…08-02Equity from €100,102 to €199,242
Key points
from the 2024 annual accounts, the last ones filed
Merger: absorbed by MULTIPHARMA
Dissolution of the company · Dissolved without liquidation · MULTIPHARMA holds all the shares · Gazette deed
Merger proposal: to be absorbed by MULTIPHARMA
Gazette deed
Registered-office move
Gazette deed
Name after signing inVisible after signing in changes role from manager to director
Discharge granted to Name hiddenVisible after signing in · General meeting of 12-12-2023 · Gazette deed
Absorbed by MULTIPHARMAmerger by absorption, April 2025
Activity
“L'achat, la vente, la préparation de produits pharmaceutiques, diététiques, homéopathiques;” (deed in French)From the articles, 6 activitiesNo NACE code in the KBO
The turnover in financial year 2024 is about €380,000. This figure is estimated from the gross margin of €145,935 and 1,393 comparable companies of the same size. It probably lies between €230,000 and €710,000. It is a rough estimate. In financial year 2022 turnover was €485,237.Financials
Is STENAPHAR profitable?
In financial year 2024, STENAPHAR made a profit of €99,140.
Where can I find the annual accounts of STENAPHAR?
STENAPHAR filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2024.